Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pseudomonas aeruginosa iron-transport receptors, primarily the TonB-dependent receptors (TBDRs), are essential outer membrane proteins that facilitate the acquisition of iron from the host environment [1, 7]. Iron is a critical nutrient for bacterial growth and virulence, but its availability is limited in the host by sequestering proteins like transferrin and lactoferrin [7, 18]. To overcome this, P. aeruginosa secretes siderophores such as pyoverdine and pyochelin and expresses specific TBDRs like FpvA, FptA, PiuA, and PirA to actively transport iron-siderophore complexes into the cell [8, 17]. Additionally, the bacterium utilizes heme receptors like PhuR and HasR to acquire iron from host hemoproteins [4, 17]. These receptors are exploited by "Trojan horse" antibiotics like cefiderocol, which conjugate a siderophore-like moiety to a beta-lactam core to bypass traditional resistance mechanisms [6, 8]. The active transport of these conjugates through TBDRs allows the drug to reach its periplasmic targets even in the presence of porin loss or efflux pump upregulation [6, 13]. However, mutations in these receptors or their regulatory genes, such as pirR, can lead to reduced drug uptake and the emergence of resistance or heteroresistance [9, 13]. Therapeutic strategies also include the use of iron mimics like gallium, which compete for transport through these systems to disrupt bacterial metabolism [18, 19]. Understanding the diversity and redundancy of these transport systems is crucial for developing effective treatments against multidrug-resistant P. aeruginosa [8, 19].
Siderophore-mediated active transport (Trojan horse strategy)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TonB-dependent iron receptor (TBDR).